🇺🇸 FDA
Patent

US 7553931

Complement depletion using recombinant human C3-derivatives

granted A61KA61K38/00A61P

Quick answer

US patent 7553931 (Complement depletion using recombinant human C3-derivatives) held by PLS-Design GmbH expires Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PLS-Design GmbH
Grant date
Tue Jun 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P11/06